The TRUST-II study (NCT04919811) is a global multicenter Phase 2 study to assess the efficacy and safety of taletrectinib in people with advanced or metastatic ROS1-positive NSCLC and other cancers.

The study started in September 2021 and is actively recruiting participants.  

The study has enrolled participants in nine countries in Asia, Europe and North America and continues to actively recruit participants in Japan, France, Italy, Spain, Canada and the United States. 

Depending on their cancer type and previous treatment, participants will be enrolled into this study and be divided into different groups (cohorts).

There are approximately 75 sites globally.
For more information, please refer to the webpage:
AnHeart Therapeutics is the sponsor for this trial.